.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

ZANTAC Drug Profile

« Back to Dashboard

Which patents cover Zantac, and what substitute generic drugs are available?

Zantac is a drug marketed by Glaxo Grp Ltd, Teligent Pharma Inc, Glaxosmithkline, Boehringer Ingelheim, and Igi Labs Inc. and is included in nine NDAs.

The generic ingredient in ZANTAC is ranitidine hydrochloride. There are forty-two drug master file entries for this compound. One hundred and forty-one suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.

Summary for Tradename: ZANTAC

Patents:0
Applicants:5
NDAs:9
Suppliers / Packagers: see list3
Bulk Api Vendors: see list84
Clinical Trials: see list5
Patent Applications: see list3
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZANTAC at DailyMed

Pharmacology for Tradename: ZANTAC

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp Ltd
ZANTAC
ranitidine hydrochloride
SYRUP;ORAL019675-001Dec 30, 1988RXYesYes► Subscribe► Subscribe
Boehringer Ingelheim
ZANTAC 150
ranitidine hydrochloride
TABLET;ORAL021698-001Aug 31, 2004OTCYesYes► Subscribe► Subscribe
Glaxo Grp Ltd
ZANTAC 150
ranitidine hydrochloride
GRANULE, EFFERVESCENT;ORAL020251-002Mar 31, 1994DISCNNoNo► Subscribe► Subscribe
Boehringer Ingelheim
ZANTAC 75
ranitidine hydrochloride
TABLET;ORAL020520-001Dec 19, 1995OTCNoNo► Subscribe► Subscribe
Boehringer Ingelheim
ZANTAC 150
ranitidine hydrochloride
TABLET;ORAL021698-002Mar 13, 2007OTCYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZANTAC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp Ltd
ZANTAC
ranitidine hydrochloride
SYRUP;ORAL019675-001Dec 30, 19884,128,658► Subscribe
Teligent Pharma Inc
ZANTAC
ranitidine hydrochloride
INJECTABLE;INJECTION019090-001Oct 19, 19844,521,431*PED► Subscribe
Glaxo Grp Ltd
ZANTAC
ranitidine hydrochloride
SYRUP;ORAL019675-001Dec 30, 19884,521,431*PED► Subscribe
Teligent Pharma Inc
ZANTAC
ranitidine hydrochloride
INJECTABLE;INJECTION019090-001Oct 19, 19844,128,658► Subscribe
Glaxo Grp Ltd
ZANTAC
ranitidine hydrochloride
SYRUP;ORAL019675-001Dec 30, 19885,068,249*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ZANTAC

Drugname Dosage Strength RLD Submissiondate
ranitidine hydrochlorideTablets150 mgZantac 15010/30/2007
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc